Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 9/2016

Open Access 01-09-2016 | Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)

A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes

Authors: Allen B. King, Akio Kuroda, Munehide Matsuhisa, Todd Hobbs

Published in: Current Diabetes Reports | Issue 9/2016

Login to get access

Abstract

Dosing guidelines for patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII), which are historically based on clinical experience and retrospective studies of patients consuming an American diet, recommend that basal insulin should represent approximately 50 % of the total daily dose (TDD). Recent prospective studies in the USA and Japan conclude that the more appropriate proportion is closer to 30–40 % of TDD. In addition, currently used formulas for calculating the carbohydrate-to-insulin ratio (CIR) and correction factor (CF) may lead to underdosing of bolus insulin by as much as 12.8–50 % for a hypothetical patient. The discrepancies between traditional formulas and data from newer studies can be accounted for by the more rigorous design of the newer studies (e.g., prospective design, controlled diets, meal omission, and frequent glucose monitoring). International differences in diet composition may also be important to consider when developing dosing recommendations for CSII.
Literature
1.•
Grunberger G, Abelseth JM, Bailey TS, et al. Consensus statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force. Endocr Pract. 2014;20:463–89. This is the major consensus document used in the USA to guide insulin dosing.
2.
Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion: a new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care. 1999;22:1779–84.CrossRefPubMed
3.
Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324:705.CrossRefPubMedPubMedCentral
4.
Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25:765–74.CrossRefPubMed
5.
Heinemann L, Fleming GA, Petrie JR, et al. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia. 2015;58:862–70.CrossRefPubMed
6.
7.
Beck RW, Tamborlane WV, Bergenstal RM, et al. T1D exchange clinic network. The T1D exchange clinic registry. J Clin Endocrinol Metab. 2012;97:4383–9.CrossRefPubMed
8.
9.
10.
American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37 Suppl 1:S14–80.CrossRef
11.
Handelsman Y, Mechanick JI, Blonde L, et al. AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17 Suppl 2:1–53.CrossRefPubMed
12.
King AB, Armstrong DU. A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: basal dosing. J Diabetes Sci Technol. 2007;1:36–41.CrossRefPubMedPubMedCentral
13.
King AB, Clark D, Wolfe GS. Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine. Endocr Pract. 2012;18:558–62.CrossRefPubMed
14.
King AB. Continuous glucose monitoring-guided insulin dosing in pump-treated patients with type 1 diabetes: a clinical guide. J Diabetes Sci Technol. 2012;6:191–203.
15.
Skyler JS, Seigler DE, Reeves ML. Optimizing pumped insulin delivery. Diabetes Care. 1982;5:135–9.
16.
Davidson PC, Hebblewhite HR, Steed RD, Bode BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract. 2008;14:1095–101.
17.
Davidson PC, Hebblewhite HR, Bode BW, et al. Statistically based CSII parameters: correction factor (CF) (1700 rule), carbohydrate-insulin ratio (CIR) (2.8 rule), and basal-to-total ratio. Diabetes Technol Ther. 2003;5:237.
18.
Walsh J, Roberts R, Bailey T. Guidelines for insulin dosing in continuous subcutaneous insulin infusion using new formulas from a retrospective study of individuals with optimal glucose levels. J Diabetes Sci Technol. 2010;4:1174–81.CrossRefPubMedPubMedCentral
19.•
Alcantara-Aragon V, Gonzalez C, Corcoy R, Ubeda J, Chico A. Carbohydrate-to-insulin ratio in a Mediterranean population of type 1 diabetic patients on continuous subcutaneous insulin infusion therapy. J Diabetes Sci Technol. 2015;9:588–92. This is a retrospective study from Spain, which found that the mean CIR in the morning was 350/TDD for breakfast and 400/TDD for other meals.
20.
Pankowska E, Szypowska A, Lipka M. Basal insulin and total daily insulin dose in children with type 1 diabetes using insulin pumps. Pediatr Diabetes. 2008;9:208–13.
21.
Alemzadeh R, Hoffmann RG, Dasgupta M, Parton E. Development of optimal kids insulin dosing system formulas for young children with type 1 diabetes. Diabetes Technol Ther. 2012;14:418–22.
22.
King AB, Armstrong DU. A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: bolus dosing. J Diabetes Sci Technol. 2007;1:42–6.
23.
Kuroda A, Kaneto H, Yasuda T, et al. Basal insulin requirement is ~30% of the total daily insulin dose in type 1 diabetic patients who use the insulin pump. Diabetes Care. 2011;34:1089–90.
24.
Kuroda A, Yasuda T, Takahara M, et al. Carbohydrate-to-insulin ratio is estimated from 300–400 divided by total daily insulin dose in type 1 diabetes patients who use the insulin pump. Diabetes Technol Ther. 2012;14:1077–80.
25.
King AB. How much do I give? Revaluation of insulin dosing estimation formulas using continuous glucose monitoring. Endocr Pract. 2010;16:428–32.
26.
King AB, Clark D, Wolfe GS. How much do I give? Dose estimation formulas for once-nightly insulin glargine and premeal insulin lispro in type 1 diabetes mellitus. Endocr Pract. 2012;18:382–6.
27.
King AB, Clark D, Wolfe GS. The number of basal rates required to achieve near-normal basal glucose control in pump-treated type 2 diabetes. Diabetes Technol Ther. 2012;14:900–3.
28.•
Nakamura T, Hirota Y, Hashimoto N, et al. Diurnal variation of carbohydrate insulin ratio in adult type 1 diabetic patients treated with continuous subcutaneous insulin infusion. J Diabetes Investig. 2014;5:48–50. This study in Japan optimized insulin dose in hospitalized patients and found that TBD = 27.3 % TDD and CIR constant should vary for each meal, being 300, 500 and 400 for breakfast, lunch and dinner, respectively.
29.•
King AB. Reassessment of insulin dosing guidelines in continuous subcutaneous insulin infusion treated type 1 diabetes. Curr Diab Rep. 2014;14:503. This review provides a detailed explanation of the derivation of current insulin dosing guidelines.
30.
Bliss M. The discovery of insulin. Chicago: The University of Chicago Press; 1984. p. 112–3.
31.
King AB. Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used. Endocr Pract. 2009;15:229–433.
32.
Heller S, Buse J, Fisher M, et al. BEGIN Basal-Bolus Type 1 Trial Investigators. Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1489–97.
33.•
King AB. Misled by the morning “fasting” plasma glucose. J Diabetes Sci Technol. 2015;9:1342–5. This commentary explains why titrating once-nightly basal insulin to morning fasting blood glucose may lead to excessive dosing.
34.
Kesavadev J, Jain SM, Muruganathan A, Das AK, Diabetes Consensus Group. Consensus evidence-based guidelines for use of insulin pump therapy in the management of diabetes as per Indian clinical practice. J Assoc Physicians India. 2014;62(7 Suppl):34–41.
35.
Mu Y, Yin S, Chinese Medical Practitioners Association, Endocrinology and Metabolism Branch, Chinese Society of Endocrinology, Chinese Diabetes Society. Insulin pump therapy guidelines for China (July 2010). J Diabetes. 2012;4:127–39.
36.
37.
Bisschop PH, de Metz J, Ackermans MT, et al. Dietary fat content alters insulin-mediated glucose metabolism in healthy men. Am J Clin Nutr. 2001;73:554–9.
38.
Cai X, Han X, Luo Y, Ji L. Analysis of insulin doses of Chinese type 2 diabetic patients with intensive insulin treatment. PLoS One. 2012;7, e38962.
39.
Gao GQ, Heng XY, Wang YL, et?al. Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes. Exp Ther Med. 2014;8:1191–6.
40.
Ma J, Zhou H, Xu H, et?al. The initial assessment of daily insulin dose in Chinese newly diagnosed type 2 diabetes. J Diabetes Res. 2016;2016. doi: 10.​1155/​2016/​7245947.
41.
Shah S, Sharma SK, Singh P, Muruganathan A, Das AK, Diabetes Consensus Group. Consensus evidence-based guidelines for insulin initiation, optimization and continuation in type 2 diabetes mellitus. J Assoc Physicians India. 2014;62(7 Suppl):49–54.
42.
Pankowska E, Blazik M, Groele L. Does the fat-protein meal increase postprandial glucose level in type 1 diabetes patients on insulin pump: the conclusion of a randomized study. Diabetes Technol Ther. 2012;14:16–22.
43.
Smart CE, Evans M, O’Connell SM, et?al. Both dietary protein and fat increase postprandial glucose excursions in children with type 1 diabetes, and the effect is additive. Diabetes Care. 2013;36:3897–902.
44.•
Laxminarayan S, Reifman J, Edwards SS, Wolpert H, Steil GM. Bolus estimation—rethinking the effect of meal fat content. Diabetes Technol Ther. 2015;17:860–6. This article describes why high-fat meals require more insulin than low-fat meals with identical carbohydrate content.
45.
Rabasa-Lhoret R, Garon J, Langelier H, Poisson D, Chiasson JL. Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralenteregular) insulin regimen. Diabetes Care. 1999;22:667–73.
46.
Hinshaw L, Dalla Man C, Nandy DK, et?al. Diurnal pattern of insulin action in type 1 diabetes: implications for a closed-loop system. Diabetes. 2013;62:2223–9.
47.
King AB, Armstrong D. A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine. Diabetes Care. 2003;26:1322.
48.•
King AB. When is enough, enough? The correlation between once-daily basal insulin doses to the fasting plasma glucose in type 2 diabetes. Endocr Pract. 2013;19:735–6. This study suggested the importance of evaluating the effect of late-night eating before raising basal insulin dose based on morning fasting glucose, which should be tested during the physiological glucose nadir between 2–6 am.
Metadata
Title
A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
Authors
Allen B. King
Akio Kuroda
Munehide Matsuhisa
Todd Hobbs
Publication date
01-09-2016
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 9/2016
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-016-0772-0

Other articles of this Issue 9/2016

Current Diabetes Reports 9/2016 Go to the issue

Microvascular Complications—Neuropathy (R Pop-Busui, Section Editor)

Diabetes and Cognitive Impairment

Economics and Policy in Diabetes (ES Huang and A Baig, Section Editors)

Diabetes Prevention Interventions in Latin American Countries: a Scoping Review

Obesity (J McCaffery, Section Editor)

Food Decision-Making: Effects of Weight Status and Age

Diabetes Epidemiology (NM Maruthur, Section Editor)

Should There be Concern About Autoimmune Diabetes in Adults? Current Evidence and Controversies

Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)

Management of Hypoglycemia in Children and Adolescents with Type 1 Diabetes Mellitus

Obesity (J McCaffery, Section Editor)

Food Insecurity and Diabetes in Developed Societies

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits